Epigallocatechin-3-Gallate Dampens Non-Alcoholic Fatty Liver by Modulating Liver Function, Lipid Profile, and Macrophage Polarization

Epigallocatechin-3-gallate (EGCG) has been shown to attenuate obesity, fatty liver disease, hepatic inflammation and lipid profiles. Here, we validate the efficacy of EGCG in a murine model of non-alcoholic fatty liver disease (NAFLD) and extend the mechanistic insights. NAFLD was induced in mice by...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Yong, Paglicawan, Laura, Soomro, Sanam, Abunofal, Omar, Baig, Sahar, Vanarsa, Kamala, Hicks, John, Mohan, Chandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918805/
https://www.ncbi.nlm.nih.gov/pubmed/33670347
http://dx.doi.org/10.3390/nu13020599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918805/
https://www.ncbi.nlm.nih.gov/pubmed/33670347
http://dx.doi.org/10.3390/nu13020599

Ejemplares similares